Bonesupport Holding ABBOEUF 77 14-Day RSI is 20.31 as of Jul. 09, 2026. GuruFocus rates BOEUF with a GF Score™ of 77/100 and a GF Value™ of $42.57 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 868 Medical Devices & Instruments companies, Bonesupport Holding AB ranks worse than 71.31% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
The industry rank for Bonesupport Holding AB's 14-Day RSI or its related term are showing as below:
BOEUF's 14-Day RSI is ranked worse than 71.31% of 868
companies
in the Medical Devices & Instruments industry
Industry Median: 46.86
vs BOEUF: 20.31
Bonesupport Holding AB (OTCPK:BOEUF) 14-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Bonesupport Holding AB 14-Day RSI Related Terms
BOEUF vs ISRG, BDX, MDLN: 14-Day RSI Comparison
For the Medical Instruments & Supplies subindustry, Bonesupport Holding AB's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bonesupport Holding AB 14-Day RSI vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bonesupport Holding AB's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Bonesupport Holding AB's 14-Day RSI falls into.
Bonesupport Holding AB (OTCPK:BOEUF) 14-Day RSI Calculation
The formula for calculating RSI is:
RSI
=
100
–
[ 100
/
( 1 + Average Gain
/
Average Loss )]
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bonesupport Holding AB (BOEUF) has a 14-Day RSI of 20.31 as of Jul. 09, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Bonesupport Holding AB and its competitors. According to the industry distribution chart, Bonesupport Holding AB ranks #619 out of 868 companies in the Medical Devices & Instruments industry, placing it in the top 71.3%.
Is Bonesupport Holding AB's 14-Day RSI too high?
Bonesupport Holding AB's current 14-Day RSI is 20.31. The Medical Devices & Instruments industry median 14-Day RSI is 46.86. Bonesupport Holding AB's value of 20.31 is 56.7% below this industry median. Based on the distribution chart, Bonesupport Holding AB ranks #619 out of 868 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Bonesupport Holding AB has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bonesupport Holding AB's 14-Day RSI compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Bonesupport Holding AB ranks #619 out of 868 companies for 14-Day RSI. This places Bonesupport Holding AB in the lower half of its industry. The industry median 14-Day RSI is 46.86. Bonesupport Holding AB's value of 20.31 is 56.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Medical Devices & Instruments company?
The median 14-Day RSI among Medical Devices & Instruments companies is 46.86, based on 868 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bonesupport Holding AB's current 14-Day RSI of 20.31 is 56.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Bonesupport Holding AB and its competitors. For the Medical Devices & Instruments industry, the median 14-Day RSI is 46.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bonesupport Holding AB's current 14-Day RSI is 20.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bonesupport Holding AB stock overvalued right now?
Based on GuruFocus' analysis, Bonesupport Holding AB (BOEUF) is currently considered Significantly Undervalued. The stock's GF Value™ is $42.57, compared to a current price of $21.40 — trading 49.7% below its estimated fair value. The current 14-Day RSI is 20.31 and 56.7% below the Medical Devices & Instruments industry median of 46.86. Bonesupport Holding AB's overall GF Score™ is 77/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Bonesupport Holding AB (BOEUF), the current 14-Day RSI is 20.31 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bonesupport Holding AB (BOEUF) Overvalued in 2026?
Based on GuruFocus' analysis, Bonesupport Holding AB stock appears to be undervalued.
The current stock price of $21.40 is trading 49.7% below its estimated GF Value™ of $42.57.
GuruFocus considers Bonesupport Holding AB to be Significantly Undervalued.
Key valuation signals for BOEUF:
14-Day RSI: 20.31
GF Value™: $42.57 vs. price of $21.40 (49.7% below fair value)
Industry Position: 56.7% below the Medical Devices & Instruments median (#619 of 868)
No single metric tells the full story. See the BOEUF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bonesupport Holding AB is a fast-growing ortho-biologics company that focuses on the treatment of bone disorders. The Company develops and commercializes injectable bio-ceramic bone graft substitutes based on its CERAMENT platform, which remodels to bone and can release pharmaceuticals to promote healing. The products of the company focus on trauma, revision arthroplasty (replacement of joint prostheses), chronic osteomyelitis (bone infection), and foot and ankle surgery. The Group manages and monitors operations in two operating segments: United States and Europe & Rest of the World (EUROW).
77GF Score
Get the complete analysis for BOEUF
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOEUF has been successfully added to your 